European Commission Approves RINVOQ for Non-Segmental Vitiligo

The European Commission has approved RINVOQ (upadacitinib) for treating non-segmental vitiligo in adults and adolescents aged 12 and older. This makes RINVOQ the first systemic medication approved in the EU for this common form of vitiligo. The approval is based on Phase 3 data demonstrating significant total body and facial repigmentation, offering a new treatment option for patients.